Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia
Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia
复制标题
DOI：
10.1159/000103575
复制
发表时间：
2007-01-01
影响因子：
3.2
通讯作者：
Kinoshita, Toshihiko
中科院分区：
文献类型：
--
作者：
Okugawa, Gaku;Nobuhara, Kenji;Kinoshita, Toshihiko
关于精神分裂症患者的尾状核体积与健康受试者相比，有不一致的报道。这是因为抗精神病药物可能会影响精神分裂症患者尾状核的体积。为了阐明哪些抗精神病药物改变了精神分裂症患者尾状核的体积，我们测量了精神分裂症患者尾状核中灰质和白质的体积。对10例精神分裂症患者进行两次核磁共振检查，测量尾状核灰质和白质体积。在第一次MRI检查后，所有患者均接受奥氮平治疗。采用阳性和阴性评定量表评定临床疗效。当症状改善时，患者接受第二次核磁共振扫描。10名健康对照受试者也接受了核磁共振检查。与健康对照组相比，精神分裂症患者尾状核灰质和白质体积减少。精神分裂症患者经奥氮平治疗后，尾状核灰质和白质体积增加。这些发现表明，奥氮平治疗可能会增加精神分裂症患者尾状核中的灰质和白质体积。版权所有(C)2007 S.Karger AG，巴塞尔。
There are inconsistent reports regarding the caudate nucleus volume in patients with schizophrenia compared with healthy subjects. The reason for this is that neuroleptic medication may affect the volume of the caudate nucleus in schizophrenic patients. To clarify which antipsychotic medication changes the volume of the caudate nucleus in patients with schizophrenia, we measured the volumes of grey and white matter in the caudate nucleus of schizophrenic patients. Ten patients with schizophrenia were examined twice by magnetic resonance imaging (MRI) to measure the grey and white matter volumes in the caudate nucleus. After the first MRI examination, all the patients were treated with olanzapine. The clinical responses were evaluated by the positive and negative rating scale. When the symptoms improved, the patients were examined by a second MRI scan. Ten healthy control subjects also underwent MRI. The schizophrenic patients had reduced volumes of grey and white matter in the caudate nucleus compared to the healthy control subjects. The volumes of grey and white matter in the caudate nucleus of the schizophrenic patients increased after treatment with olanzapine. These findings suggest that treatment with olanzapine may increase the grey and white matter volumes in the caudate nucleus in patients with schizophrenia. Copyright (c) 2007 S. Karger AG, Basel.